Novalis invests in Enzyre for haemophilia monitoring device

28 July 2020 (Last Updated July 28th, 2020 10:04)

Novalis Biotechnology Incubation has invested in Enzyre to support the development of Enzypad, a hand-held diagnostic and monitoring device for haemophilia.

Novalis invests in Enzyre for haemophilia monitoring device
Enzyre signed a collaboration agreement with Takeda last year for the development of Enzypad in congenital bleeding disorders. Credit: Enzyre.

Novalis Biotechnology Incubation has invested in Enzyre to support the development of Enzypad, a hand-held diagnostic and monitoring device for haemophilia.

Novalis participated as a co-financer in the Dutch Government’s €1.4m ($1.64m) Corona Bridge Loan initiative to back up the innovative start-ups and scale-ups.

Enzyre, a spin-out from Radboud University Medical Center in the Netherlands, was set up to develop a near-patient test (NPT) device called Enzypad to measure biomarkers in body fluids.

The company is currently developing the device for monitoring haemophilia by offering a real-time picture of a patient’s blood coagulation status. The result of each test made by a patient is sent automatically to the treating physicians through an app on a mobile phone.

Last year, the company signed a collaboration agreement with Takeda for the development of Enzypad in congenital bleeding disorders.

Enzyre CEO Dirk Pollet said: “We are pleased to welcome Novalis Biotechnology Incubation to our investor base. The Novalis team is very well aligned with Enzyre’s strategy to ‘bring the laboratory to the patient’, enabling them to avoid hospital visits.

“We firmly believe there is a huge demand for technology that empowers patients and allows healthcare workers to provide the best therapy without delay and increased cost. The Enzypad is able to meet this demand.”

There is a growing need for NPT tools that enable remote personalised and data-based disease management via telemedicine and eliminate the need for routine hospital visits, the company noted.

Novalis co-founder Prof Wim Van Criekinge said: “Near patient testing presents a major opportunity in today’s world to obtain an improved treatment outcome for patients. More and better data is an essential element in our drive to advance healthcare.

“We were impressed by the Enzyre team and Enzypad technology, which has many application areas beyond coagulation testing. Our investment in Enzyre perfectly matches our strategy of investing in innovative breakthrough technology in life sciences.”